Inhaled RNA therapy cuts lung inflammation after severe infections in preclinical tests

NTU Singapore is working with China's Southern University of Science and Technology (SUSTech) and Swedish biotechnology company Lipigon Pharmaceuticals AB to develop a new inhaled treatment aimed at helping patients recover faster from severe lung infections. The treatment is designed to reduce excessive inflammation in the lungs, which can continue even after viruses or bacteria have been cleared from the body.